索拉非尼可预防异基因造血干细胞移植后急性髓系白血病复发。 - Suppr

Suppr

超能文献

Sorafenib prevents AML relapse after allo-HSCT.

作者信息

Romero Diana

机构信息

Nature Reviews Clinical Oncology, .

出版信息

Nat Rev Clin Oncol. 2020 Oct;17(10):591. doi: 10.1038/s41571-020-00431-7.

DOI:10.1038/s41571-020-00431-7

PMID:32843740

Abstract

摘要

相似文献

Sorafenib prevents AML relapse after allo-HSCT.

Nat Rev Clin Oncol. 2020 Oct;17(10):591. doi: 10.1038/s41571-020-00431-7.

Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):506-508. doi: 10.1016/j.clml.2019.04.004. Epub 2019 Apr 18.

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Cancer. 2018 May 1;124(9):1954-1963. doi: 10.1002/cncr.31295. Epub 2018 Mar 6.

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.

Cancer. 2017 Aug 1;123(15):2867-2874. doi: 10.1002/cncr.30680. Epub 2017 Apr 7.

Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1674-1681. doi: 10.1016/j.bbmt.2019.04.018. Epub 2019 Apr 19.

[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].

Zhonghua Nei Ke Za Zhi. 2016 Aug 1;55(8):634-6. doi: 10.3760/cma.j.issn.0578-1426.2016.08.014.

Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

Clin Lymphoma Myeloma Leuk. 2015 May;15(5):298-302. doi: 10.1016/j.clml.2014.12.005. Epub 2014 Dec 12.

[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].

Zhonghua Nei Ke Za Zhi. 2016 Apr 1;55(4):293-7. doi: 10.3760/cma.j.issn.0578-1426.2016.04.009.

[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].

Zhonghua Nei Ke Za Zhi. 2018 May 1;57(5):351-354. doi: 10.3760/cma.j.issn.0578-1426.2018.05.009.

Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant. 2021 Jan;56(1):293-296. doi: 10.1038/s41409-020-01015-w. Epub 2020 Aug 4.

引用本文的文献

Nanomaterial-assisted theranosis of bone diseases.

Bioact Mater. 2022 Dec 26;24:263-312. doi: 10.1016/j.bioactmat.2022.12.014. eCollection 2023 Jun.

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

RSC Med Chem. 2022 May 23;13(7):798-816. doi: 10.1039/d2md00067a. eCollection 2022 Jul 20.

Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

J Hematol Oncol. 2021 Jan 6;14(1):4. doi: 10.1186/s13045-020-01017-7.

本文引用的文献

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.

Lancet Oncol. 2020 Sep;21(9):1201-1212. doi: 10.1016/S1470-2045(20)30455-1. Epub 2020 Aug 10.

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN).

J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验